ArticleAnnals of hematology2026
Elevated tricuspid regurgitation velocity in adults with sickle cell disease and HbAA controls in Kinshasa, Democratic Republic of the Congo: a comparative cross-sectional study.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension is a severe complication of sickle cell disease (SCD) and is associated with increased morbidity and mortality. Elevated tricuspid regurgitation velocity (TRV) assessed by echocardiography is commonly used as a screening marker to estimate the risk of pulmonary hypertension in adults with SCD. The objective of this study was to determine the prevalence of elevated TRV and to identify factors associated with elevated TRV in adults with sickle cell disease compared with HbAA clinical controls in Kinshasa. We conducted a comparative cross-sectional study between January 2024 and January 2025 including 71 adults with SCD in steady state (SCD excluding HbSC) and 71 HbAA clinical controls, individually matched by age (± 5 years) and sex. Participants were recruited independently of TRV status. Sociodemographic, clinical, biological, and echocardiographic data were collected. Transthoracic Doppler echocardiography was performed and TRV was measured from multiple ac in the absence of right heart catheterization to assess PH, with the highest value retained. Elevated TRV was defined as TRV ≥ 2.9 m/s. Logistic regression analyses were used to identify factors independently associated with elevated TRV. The mean age was 31.8 ± 5.8 years in the SCD group and 32.8 ± 5.6 years in controls. The overall prevalence of elevated TRV was 10.6%, and was significantly higher among patients with SCD (18.3%) compared with HbAA controls (2.8%, p < 0.001). In multivariable analysis, factors independently associated with elevated TRV were SCD status (adjusted OR 3.52, 95% CI 1.87–5.19), systemic arterial hypertension (aOR 2.61, 95% CI 1.96–4.60), and elevated C-reactive protein (> 6 mg/L) (aOR 2.79, 95% CI 1.98–3.88). Elevated TRV, a marker of increased risk for pulmonary hypertension, was observed in nearly one in five adults with sickle cell disease in Kinshasa. Sickle cell disease status, systemic arterial hypertension, and systemic inflammation were independently associated with elevated TRV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.